Insider Brief
- SquareMind raised $18 million to support the U.S. and European launch of Swan, its robotic full-body skin imaging platform designed for dermatology practices.
- The round was led by Sonder Capital, co-founded by Fred Moll, with participation from the Deeptech 2030 Fund, Bpifrance, Adamed Technology, Calm/Storm Ventures and Teampact Ventures.
- Swan uses a robotic arm to capture standardized, full-body dermoscopic images in minutes and pairs them with AI software that helps dermatologists track new or changing lesions over time while keeping final clinical decisions with the physician.
France-based medical robotics company SquareMind has raised $18 million, including previously undisclosed pre-Series A financing, as it prepares to launch its robotic skin imaging platform for dermatology practices in the United States and Europe.
According to the company, the round was led by Sonder Capital, a California venture fund co-founded by Fred Moll, with participation from the Deeptech 2030 Fund, managed by a Bpifrance initiative on behalf of the French government, along with Adamed Technology, Calm/Storm Ventures and Teampact Ventures.
“We are excited to partner with Sonder Capital and all our investors as we ready ourselves to bring Swan to market and respond to the strong traction we are seeing from practices and hospitals,” co-founder and CEO Ali Khachlouf said in the announcement. “Dermatologists are operating under increasing pressure, facing strong cognitive load and fatigue. Our technology acts as their companion, helping to reduce this burden, optimize their time, and support comprehensive documentation so they can stay focused on patient care and clinical decision-making.”
What Will SquareMind Do With The Funding?
The company said the funding will be used to expand its commercial, engineering and customer support teams ahead of the near-term rollout of Swan, its robotic full-body skin imaging system designed to help dermatologists perform faster and more standardized skin exams.
According to Khachlouf, skin screening is the highest-volume procedure in dermatology, but demand continues to outpace capacity as aging populations drive more patients into clinics. Long wait times and short appointment windows can make it difficult for physicians to fully document changes in a patient’s skin over time, a critical step in detecting melanoma and other skin cancers early.
SquareMind says about 80% of melanomas are newly appearing lesions rather than changes to existing moles, making full-body documentation especially important.
Swan is designed to automate that process. The system uses a robotic arm to capture standardized, full-body dermoscopic images of a patient’s skin, creating a level of detail typically associated with close-up mole examinations across the entire body rather than isolated spots.
The patient stands in a private exam room while the robot moves around them, guided by visual and audio prompts. The session is contactless and completed in a matter of minutes, according to the company.
The platform is paired with AI-based review software that helps physicians identify and track new or changing lesions over time, though final clinical decisions remain with the dermatologist.
SquareMind describes the system as an “augmented dermatoscope,” intended to reduce physician workload rather than replace clinical judgment. The company said the goal is to help dermatologists manage rising patient volumes while improving documentation and consistency across exams.
The Swan platform is already FDA-listed in the United States and CE-marked in Europe, allowing commercial use in both markets.
Image credit: SquareMind
